Medipost Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
996
1,809
2,698
5,368
1,446
Depreciation, Depletion & Amortization
2,797
3,153
4,753
4,724
4,730
Other Funds
3,351
6,674
5,543
7,324
2,716
Funds from Operations
4,407
194
1,748
5,738
4,655
Changes in Working Capital
2,698
373
7,167
1,610
3,118
Net Operating Cash Flow
1,709
567
5,419
4,128
1,537
Capital Expenditures
32,878
31,369
9,491
9,925
7,222
Sale of Fixed Assets & Businesses
-
11
9
58
-
Purchase/Sale of Investments
25,293
7,367
3,087
9,443
2,088
Net Investing Cash Flow
7,491
23,045
6,852
19,286
5,237
Issuance/Reduction of Debt, Net
7,179
37,850
-
-
-
Net Financing Cash Flow
9,268
43,060
5,543
8,014
2,716
Net Change in Cash
3,486
19,443
6,731
15,321
994
Free Cash Flow
20,383
22,781
6,546
4,991
749
Other Sources
368
1,303
480
155
509
Change in Capital Stock
1,262
1,464
-
690
-
Exchange Rate Effect
-
5
3
79
10
Other Uses
275
357
936
131
612

About Medipost Co.

View Profile
Address
21 Daewangpangyo-ro 644 beon-gil
Seongnam GY 13494
Korea, Republic Of
Employees -
Website http://www.medi-post.co.kr
Updated 09/14/2018
Medipost Co., Ltd. engages in the development and manufacture of stem cell biotechnology products. It operates through the following business divisions: Cord Blood Bank, Stem Cell Therapy, Health Functional Food, Import and Distribution of Natural Cosmetics and Healthcare Services. The Cord Blood Bank division is involved in collecting and storing stem cells from the newborn's umbilical cord.